Jeffrey F Scherrer1,2, Joanne Salas1,2, Kathleen K Bucholz3, F David Schneider1, Thomas Burroughs4, Laurel A Copeland5,6,7, Mark D Sullivan8, Patrick J Lustman3,9. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA. 2. Harry S. Truman Veterans Administration Medical Center, Columbia, MO, USA. 3. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. 4. Saint Louis University Center for Outcomes Research, St. Louis, MO, USA. 5. Center for Applied Health Research, Baylor Scott & White Health, and Central Texas Veterans Health Care System, USA. 6. Texas A&M Health Science Center, Bryan, TX, USA. 7. UT Health Science Center, San Antonio, TX, USA. 8. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. 9. The Bell Street Clinic, VA St. Louis Health Care System-John Cochran Division, St. Louis, MO, USA.
Abstract
PURPOSE: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. METHODS: A retrospective cohort design was used to model onset of new depression diagnosis among 11 462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30 days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. RESULTS: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR = 1.27; 95%CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. CONCLUSIONS: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30% greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.
PURPOSE: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. METHODS: A retrospective cohort design was used to model onset of new depression diagnosis among 11 462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30 days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. RESULTS: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR = 1.27; 95%CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. CONCLUSIONS: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30% greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.
Authors: Susan M Frayne; Donald R Miller; Erica J Sharkansky; Valerie W Jackson; Fei Wang; Jewell H Halanych; Dan R Berlowitz; Boris Kader; Craig S Rosen; Terence M Keane Journal: Am J Med Qual Date: 2009-10-23 Impact factor: 1.852
Authors: Suzanne Nielsen; Maureen Hillhouse; Roger D Weiss; Larissa Mooney; Jennifer Sharpe Potter; Joshua Lee; Marc N Gourevitch; Walter Ling Journal: Am J Addict Date: 2013-09-24
Authors: Jarred W Younger; Larry F Chu; Nicole T D'Arcy; Kiley E Trott; Laura E Jastrzab; Sean C Mackey Journal: Pain Date: 2011-04-30 Impact factor: 6.961
Authors: René Fernando Rodriguez; Javier Mauricio Castillo; Maria Del Pilar Castillo; Paola Daza Nuñez; Mario Fernando Rodriguez; José Manuel Restrepo; Jorge Martin Rodriguez; Yamileth Ortiz; Ana Maria Angel Journal: Clin Ther Date: 2007-04 Impact factor: 3.393
Authors: Jeffrey F Scherrer; Dragan M Svrakic; Kenneth E Freedland; Timothy Chrusciel; Sumitra Balasubramanian; Kathleen K Bucholz; Elizabeth V Lawler; Patrick J Lustman Journal: J Gen Intern Med Date: 2013-10-29 Impact factor: 5.128
Authors: Jeffrey F Scherrer; Joanne Salas; F David Schneider; Kathleen K Bucholz; Mark D Sullivan; Laurel A Copeland; Brian K Ahmedani; Thomas Burroughs; Patrick J Lustman Journal: J Affect Disord Date: 2016-12-21 Impact factor: 4.839
Authors: Rebecca Arden Harris; Henry R Kranzler; Kyong-Mi Chang; Chyke A Doubeni; Robert Gross Journal: Drug Alcohol Depend Date: 2019-11-02 Impact factor: 4.852
Authors: Jeffrey F Scherrer; Brian Ahmedani; Kirsti Autio; Lynn Debar; Patrick J Lustman; Lisa R Miller-Matero; Joanne Salas; Scott Secrest; Mark D Sullivan; Lauren Wilson; Sarah Skiold-Hanlin Journal: J Psychiatr Brain Sci Date: 2020-04-28